NYSE$AGL
agilon health inc. · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
agilon health reported a 47% increase in revenue, driven by a 43% growth in Medicare Advantage membership.
agilon health announced its Q3 2021 results, featuring a 47% increase in total revenue to $459 million, driven by a 43% growth in Medicare Advantage membership. Total members on the agilon platform increased by 83% year-over-year to 236,500. The company updated its full-year 2021 guidance for membership, revenue, and Adjusted EBITDA and expects total membership in 2022 to grow by more than 45%.
- Total revenue increased 47% year-over-year, reaching $459 million.
- Medicare Advantage membership grew by 43% compared to the previous year.
- Total membership on the agilon platform increased by 83% year-over-year, totaling 236,500 members.
- Net loss was $36 million, compared to a net loss of $12 million in 2020.
Headline financials
Revenue & EPS history
agilon health · Revenue · Quarterly
$459M
Revenue by segment
agilon health · $459M total across 2 segments · Q3 2021
- Medical Services Revenue$458M+46.8%99.8%
- Other Operating Revenue$967K+1.8%0.2%
Forward guidance
agilon health raised its 2021 guidance for membership, revenue, and Adjusted EBITDA. The company expects total membership in 2022 will increase by more than 45%, with Medicare Advantage growing over 40%.
Tailwinds
- Ending MA Members between 185,000 and 186,000
- Ending DCE Members between 50,000 and 52,000
- Total revenues between $1,820 million and $1,825 million
- Adjusted EBITDA between $(40) million and $(37) million
- Total members live on the platform will increase by over 45% on a year-over-year basis during 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2021
-2.6%
Avg return
Earnings day
-0.0%
Avg return
5 days after
+6.7%
Avg return
30 days after
50%
10 / 20 earnings
Positive
+20.2%
Q4 2025
Best reaction
-36.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.2% | +122.0% | +256.9% | |
| Q4 2025 | +20.2% | +13.4% | -20.8% | |
| Q3 2025 | +5.1% | -9.0% | -9.9% | |
| Q1 2025 | -25.6% | -33.4% | -51.6% | |
| Q4 2024 | -7.4% | -17.9% | +23.7% | |
| Q3 2024 | -36.1% | -35.1% | -24.7% | |
| Q2 2024 | -12.7% | -14.6% | -36.8% | |
| Q1 2024 | +7.5% | +7.5% | +40.8% | |
| Q4 2023 | +3.1% | -2.1% | -1.1% | |
| Q3 2023 | -13.1% | -19.0% | -33.1% | |
| Q2 2023 | +0.7% | +3.7% | -7.9% | |
| Q1 2023 | -3.4% | -6.6% | -18.9% | |
| Q4 2022 | +15.4% | +14.8% | +12.0% | |
| Q3 2022 | -12.7% | -7.9% | -8.6% | |
| Q2 2022 | -3.3% | -0.4% | -20.3% | |
| Q1 2022 | -8.6% | -19.4% | +1.3% | |
| Q4 2021 | +10.6% | +2.4% | +31.7% | |
| Q3 2021 | +2.7% | +3.6% | -9.5% | |
| Q2 2021 | -3.8% | -6.3% | -3.4% | |
| Q1 2021 | +6.3% | +4.0% | +14.0% | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro